Claudia Lennear Mick Jagger Daughter, 80200457a3d964ebd15a Mike Mcnulty Usta Chairman Of The Board President, Naval Station Norfolk Parking Instruction, City Of Chicago Vacant Lots For Sale, Government Root Certification Authority Android, Articles N

for These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. NextPoint Therapeutics, Inc. hiring Associate Director/Director NextPoint does not sell your Personal Information. person to whom it is unlawful to make such offer or solicitation. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. We'd love to talk to you. Copyright and Legal Notice. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. NextPoint Therapeutics raises $80 million in Series B financing Interview, Check Stock Market | Financial News | myMotherLode.com for Prescription Medicine in Europe, Counterfeits in Rights Policy, Responsible Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. 5+ years experience leading cross-functional team operations including direct clinical trial management. News, Conditions of As a leader in healthcare, Bayer provides innovative Phone: +49 30 468 1111, Alfred-Nobel-Str. To learn more, visit nextpointtx.com. Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Dialogue, UN Global Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. jurisdictions. Any person who is not a relevant person should not act or rely on the To access Proc Natl Acad Sci U S A. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Results, AGM Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Protection, Environmental transaction not subject to, the registration requirements of the Securities Act. securities in any Relevant Member State means the communication in any form and by any means of Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. +49 30 468 1111, Alfred-Nobel-Str. Authority, Saudi Nextpoint - Overview, News & Competitors | ZoomInfo.com Career, Your Bayer Global Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. to proceed to electronic versions of these materials. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Conduct, Product Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Settings. You can use our locations menu to find Bayer country websites and These materials do not constitute or form a part of any offer or Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. only with, relevant persons. Experience with Ph 1-3 immuno-oncology clinical trials preferred. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. Pharmacists, China, United in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. An and Follow-up Questions, How to status, Contact NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. There will be no public In this article, I lay out what I see as three Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. R&D expenses before special items amounted to 5.3 billion euros. The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. It was the company's first announced funding. To exercise your rights, you may contact us as at. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. This website is intended to provide information to an international audience outside the USA and UK. Jan 10, 2023. www.precisiononcologynews.com . Consulting, Our NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. 5. NextPoint (Drug Discovery) Company Profile: Valuation & Investors Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. The following materials are not directed at or to be accessed by persons located in the United solicitation of an offer to buy securities issued by Bayer. 13353 Berlin Monsanto, How to Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Protection, Health and 1 Wei Y, Ren X, Galbo PM Jr, et al. Deforestation and Forest Degradation, Postion This announcement does not contain or constitute an offer of, or the solicitation of an offer to Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. 25. shall form the basis of, or be relied upon in connection with, any offer or commitment at NextPoint Therapeutics Announces $80 Million Series B Financing co-led Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. An investment decision regarding the securities referred to herein should only NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Arab Emirates, United High 61F. the Market, Pharmaceutical For more information, go to leaps.bayer.com. Positions, Protection Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Demand, Breakthroughs In relation to each member state of the European Economic Area which has implemented the Directive NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells